Topics
Innovation
Laser
Medical
Practice
Research
Surgical
Training
New Technologies and Policy Shifts Are Reshaping the Delivery of Glaucoma Care.
View Issue
Supported by Allergan
View Supplement
In This Issue
Steven D. Vold, MD
Kevin Kaplowitz, MD, and Osamah Saeedi, MD
New findings of glaucomatous changes in Schlemm canal cells point to the possibility of directing treatment to restore the function of diseased outflow tissue.
Mark Johnson, PhD, and W. Daniel Stamer, PhD
Do the risks outweigh the benefits?
Aaron M. Marble, BS; Bradley P. Roth, MS; and Barbara A. Smit, MD, PhD
Jeffrey R. SooHoo, MD; Leonard K. Seibold, MD; and Malik Y. Kahook, MD
Albert S. Khouri, MD, and Steven D. Vold, MD
Where are we today, and where are we headed?
Robert Chang, MD
Can this technology really help you be a better doctor?
Kyle Smith, MD
The next several years should bring advances.
David I. Green, BS, and Yvonne Ou, MD
Drugs and delivery systems in development offer the hope of better options for individualized treatment.
Sunita Radhakrishnan, MD
Patients' visual outcomes are important but often overlooked.
Cynthia Mattox, MD
Physicians must strike a balance in the face of complexity.
Andrew G. Iwach, MD
John Berdahl, MD, and Quang H. Nguyen, MD
How payers are guiding patients away from specialists' offices.
Ruth D. Williams, MD
First, build your foundation.
David B. Mandell, JD, MBA, and H. Michael Lewellen, CFP
Shakeel Shareef, MD
Subscribe
Stay up to date all on all things Glaucoma by signing up to receive our print publication or subscribe to our email alerts.